Of the biomarker-directed therapies for esophageal neuroendocrine tumor, 1 is FDA-approved in at least one setting and 0 have NCCN guidelines in at least one setting [3].

There is 1 clinical trial for esophageal neuroendocrine tumor, of which 1 is open and 0 are completed or closed. Of the trial that contains esophageal neuroendocrine tumor as an inclusion criterion, 1 is phase 2 (1 open).

Abemaciclib is the most common intervention in esophageal neuroendocrine tumor clinical trials.